This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Matthias Müllenbeck
Executive Director & Head Global Licensing and Business Development Enabling Technologies Biopharma, Global Business Development and Alliance Management at Merck KGaA, Darmstadt, Germany


Matthias is Executive Director & Head of Global Business Development Enabling Technologies for Merck KGaA, Darmstadt Germany. His team ensures execution of global deals for all Merck Healthcare franchises in the areas of technologies, asset outlicensing, new venture creation, diagnostics, devices, manufacturing, academic partnerships, and digital. Matthias is an entrepreneurial-minded, result-driven, and communication-strong pharma business development leader with more than 10 years of international experience across the therapeutic areas oncology, immuno-oncology, and immunology. He successfully developed corporate partnering strategies and led negotiation teams on more than 60 transactions throughout his career, including transformative deals with deal-lifetime values of greater than USD 4 billion. Matthias has directly negotiated key deals for Merck such as the alliances with Mersana and Sutro to enable Merck’s entry into the ADC space, the purchase of the oncology pipeline from Vertex, the NewCo formation of Telios Pharma Inc., and most recently the co-development and co-commercialization agreement with GSK on Bintrafusp alfa. He has lived and worked in Germany, the U.S., England, and Gabon. Matthias holds a Ph.D. in Immunology from the Humboldt University Berlin and a MBA from Kellogg-School of Management, Northwestern University.

Agenda Sessions

  • Oncology: The in-rush of funds for IO and non-IO

    On Demand